Endosense raises $36 million for TactiCath launch: European roll-out of Endosense's TactiCath force-sensing cardiac arrhythmia ablation catheter will be funded by a $36 million "Series B" private placement, announced Sept. 1. Proceeds also will be used for a U.S. clinical trial to support a PMA submission, according to the company. Headquartered in Geneva, Endosense received European CE mark approval in May for TactiCath treatment of supraventricular tachycardia of the right atrium. TactiCath "is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure," and it "has the potential to improve the effectiveness, safety and reproducibility" of treatment, according to Endosense. Founded in 2003, the firm estimates that the competitive, worldwide catheter ablation market is worth over $500 million annually. The financing round was led by Edmond de Rothschild Investment Partners
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Ellipsis said it will use its new funding to expand its AI-powered voice assistant Sage across health systems. Ellipsis is part of the global vocal biomarker market, which is expected to exceed $9bn by the end of 2033, according to a research market report.
